trending Market Intelligence /marketintelligence/en/news-insights/trending/8rcfMfryhbPD4N52BNHGLA2 content esgSubNav
In This List

AbbVie plaque psoriasis drug clears another phase 3 trial

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


AbbVie plaque psoriasis drug clears another phase 3 trial

AbbVie Inc. said another phase 3 clinical trial of risankizumab in plaque psoriasis patients met its main goal.

Results from the IMMhance study showed that after 16 weeks of treatment, patients in the risankizumab arm experienced an improvement in their condition when compared to placebo.

Furthermore, in the risankizumab arm, 87% of the patients maintained improvement in disease until the end of one year. In the group that switched to placebo, 61% of the patients maintained improvements.

Top-line results announced in October showed that after 16 weeks of treatment, the drug was better at treating moderate to severe chronic plaque psoriasis when compared to ustekinumab, adalimumab or placebo.

AbbVie is developing risankizumab in collaboration with Boehringer Ingelheim GmbH.

The drug is also being evaluated in Crohn's disease, ulcerative colitis and psoriatic arthritis.